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Abstract
Objectives—HSV-2 biomarkers are often used in adolescent sub-Saharan HIV prevention 
studies, but evaluations of test performance and disclosure outcomes are rare in the published 
literature. Therefore, we investigated the proportion of ELISA-positive and indeterminant samples 
confirmed by Western blot (WB); the psychosocial response to disclosure; and whether reports of 
sexual behavior and HSV-2 symptoms are consistent with WB confirmatory results among 
adolescent orphans in Kenya.
Methods—In 2011, 837 Kenyan orphan youth in grades 7 and 8 enrolled in an HIV prevention 
clinical trial with HSV-2 biomarker outcomes. We used a modified algorithm for the Kalon 
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HSV-2 ELISA to improve specificity; positive and indeterminate results were WB-tested. We 
developed culturally sensitive protocols for disclosing positive results and documented 
psychosocial responses, reports of sexual contact, and HSV-2 symptoms.
Results—28 adolescents (3.3%) were identified as HSV-2 seropositive; 6 as indeterminate. Of 
these, 22 positive and all indeterminants were WB-tested; 20 and 5, respectively, were confirmed 
positive. Most youth reported moderate brief stress after disclosure; 22% reported longer and more 
severe distress. Boys were more likely to be in the latter category. Self-reported virginity was 
highly inconsistent with WB confirmed positives.
Conclusions—The higher than manufacturer cut-off for Kalon ELISA modestly reduced the 
rate of false positive test results but also increased false negatives. Investigators should consider 
the risk-benefit ratio in deciding whether or not to disclose HSV-2 results to adolescent 
participants under specific field conditions.
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INTRODUCTION
Herpes Simplex Virus type 2 (HSV-2) is the primary cause of genital herpes [1], particularly 
in sub-Saharan Africa. Because nearly all HSV-2 infections are sexually acquired, type-
specific HSV-2 antibodies in serum imply anal-genital infection.[2] Infections are life-long 
with intermittent clinical and subclinical viral reactivation and mucosal shedding.[1] Only 
10–25% of people with HSV-2 antibodies are aware that they have genital herpes.[1] 
Symptoms vary widely, and infected persons may be asymptomatic. Although there is no 
cure, systemic antiviral drugs can partially control the signs and symptoms of herpes 
episodes and can be used as daily suppressive therapy.[2]
Prevalence of genital herpes in the adult general population in sub-Saharan Africa is high, 
ranging from 30% to 80% in women and from 10% to 50% in men, as assessed by 
serological detection of HSV-2 antibodies.[3–7] In Kenya, the population-based prevalence 
among those 15–64 years old is 42% for females and 26% for males.[8] In Nyanza Province, 
which has the highest HIV prevalence in the country, HSV-2 prevalence among 13–14 year 
olds is estimated at 9% for females and 4% for males, and among 15–19 year olds at 28% 
and 17% respectively.[9]
HSV-2 is an important risk factor for HIV.[1] Meta-analyses of longitudinal studies have 
found a three-fold increase in HIV infection with HSV-2. [10, 11] Among Kenyans, HIV 
prevalence is 16% among HSV-2 seropositive persons compared to 2% among 
seronegatives.[8]
Besides its importance as an HIV risk factor, HSV-2 has become increasingly used as a 
biomarker to corroborate adolescent self-report of sexual behavior, which is often 
inconsistent.[12–14] HSV-2 is also considered an important clue in determining the path of 
transmission for HIV positive youth, whether vertical or through sexual contact.[15] 
Because of its relatively high prevalence among sexually transmitted infections, the 
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inclusion of HSV-2, along with HIV biomarkers, has become the scientific standard for 
evaluating youth prevention interventions in sub-Saharan Africa,[16–20] although some 
have more recently questioned its utility for this purpose.[21]
Despite the potential importance of HSV-2 as a biomarker, studies to evaluate disclosure of 
results to sub-Saharan adolescents are lacking. Some U.S. studies have raised concerns 
about disclosure after serological screening in the absence of pre-existing symptoms or 
diagnosis, given the low calculated positive predictive value (PPV) of existing enzyme-
linked immunosorbent assay (ELISA) tests [22] and the possibility of psychosocial harm.
[23] Young adolescents are likely to have a low prevalence of HSV-2 infection,[19, 16] and 
PPV for all diagnostic tests drops greatly when prevalence is low, resulting in a potentially 
high rate of false positives.[24] Nevertheless, a recent review of the extant literature 
concluded that HSV-2 diagnosis by type-specific serological testing did not result in long-
term psychosocial harm in most persons without an identified history of genital herpes.[25] 
That review, however, was limited to studies with adults from developed countries. 
Moreover, conclusions were aimed at clinicians, who were advised to offer HSV-2 testing 
selectively to “appropriate” patients. Among published sub-Saharan adolescent prevention 
studies collecting biomarkers, most have not disclosed HSV-2 results to participants [16, 18, 
20] while others have.[17, 19] No research guidelines on the disclosure of HSV-2 biomarker 
test results in community studies of sub-Saharan African adolescents are available in the 
scientific or regulatory literature.
The study is unique in examining the performance of a commonly used serological HSV-2 
test for Kenyan adolescents and the outcomes of a culturally sensitive protocol for disclosing 
results. Since the response of African youth to positive test results within the context of an 
HIV prevention trial was unknown, we also examined findings related to disclosure of 
positive HSV-2 results to Kenyan orphan adolescents. This paper addresses the following 
research questions:
1. Following disclosure, what proportion of ELISA-positive samples was confirmed 
by WB?
2. What was the psychosocial response reported by participants?
3. Were participants' report of sexual behavior and HSV-2 symptoms consistent with 
WB confirmatory tests?
Study findings provide important guidance to scientists about the ethical disclosure of 
HSV-2 biomarkers in adolescent African HIV prevention research.
METHODS
Sample and Setting
This study was conducted in Siaya County, in Nyanza Province, Kenya. Twenty-six primary 
schools were selected for a randomized controlled trial to determine whether providing 
orphans with school fees can prevent HIV and HIV-related risk behaviors.[19, 24] To be 
included, schools had to have at least 20 orphans (one or both parents deceased) in grades 7 
and 8. All orphans in grades 7 and 8 at selected schools were eligible.
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HSV-2 Biomarker sample collection and testing
Whole blood was obtained aseptically by venipuncture at remote study sites and transported 
on ice to a local laboratory where serum was prepared and stored at 4°C until weekly 
transport to the AMPATH Reference Laboratory in Eldoret, Kenya for ELISA testing using 
a type specific HSV-2 ELISA (Kalon Biological Ltd., Guildford, UK). Serum was stored at 
4°C until testing. Kalon testing was performed by a single technician from October, 2011 to 
January, 2012. After testing, samples were frozen at −20°C until selected samples (described 
below) were shipped on dry ice to the Virology Laboratory at the University of Washington 
where confirmatory WB testing was performed in June, 2014 by a single technician without 
knowledge of ELISA results. [30]
Kalon testing was performed according to the manufacturer's instructions with absorbance 
values obtained using a microtiter platereader at 450nm wavelength blanked on air. Index 
values were calculated from the absorbance value of the test sample compared to a 
manufacturer-supplied calibrator for the kit. The manufacturer's cut-off index value defining 
a positive result is 1.1.[26] Numerous reports in the literature describe performance issues 
with HSV-2 ELISA tests in sub-Saharan African populations using manufacturers' cut-offs, 
particularly in low prevalence groups such as adolescents.[26–29] In an effort to improve 
the specificity of the test, we employed a modified algorithm for test result interpretation in 
the study. Samples were initially tested in single wells; samples with initial index values < 
0.9 were considered negative, those with initial index values > 2.5 were considered positive, 
and no further ELISA testing was performed on those sera. Samples with initial index values 
between 0.9 and 2.5 were retested in duplicate. Final results were considered negative if 
retest index results were < 0.9; positive if retest results were ≥ 1.5 and indeterminant if retest 
results were between 0.9 and 1.5, or discordant.
Based on previously published evaluations of Kalon test performance in Sub-Saharan 
African populations using the higher index value cut-off of 1.5 to interpret results compared 
to the WB reference standard, [26] we assumed ELISA sensitivity of 94% and specificity of 
92% for the study-specific algorithm. Positive and negative predictive values (PPV and 
NPV, respectively) of the Kalon test were calculated using standard formulas:
Sub-Study Procedures
University-educated male and female registered nurse researchers were trained in the study 
protocol as follows: nurses met with same-gender participants for disclosure at a private 
place (e.g., home or clinic room). If the participant was under 18 years, the nurses met first 
with the guardian to disclose the diagnostic findings and review a CDC adapted fact sheet on 
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HSV-2. The participant then joined to receive the same information. The nurse answered 
questions, provided the fact sheet with his/her contact information for further questions, 
gave a referral form for treatment, and requested permission to return for follow-up in a few 
months. The nurse then talked with the adolescent alone about transmission, symptoms, or 
other questions. After disclosure, nurse researchers summarized their observations of 
guardian and participant behavior and questions/comments during the meeting, including 
participant's self-report of sexual behavior and symptoms. All participants were re-contacted 
several months later for a follow-up interview at a private place of participant's choice. 
Nurses transcribed their notes and sent them in English to investigators in the U.S. who 
reviewed, coded, and entered data.
Measures—Using content analysis of disclosure and follow-up interview notes, measures 
were coded by a senior research scientist, in consultation with the interviewers, as follows: 
I) participants' emotional response at follow up (1=low or no emotional distress exhibited; 
2=reported distress for a few days or weeks but resolved; 3=distressed for a month or more 
but resolved; 4=prolonged psychosocial effects with adverse emotional, social, academic 
effects); II) guardian type (mother, sibling, stepmother, grandparent, aunt/uncle, spouse); III) 
participants' perception of guardian or family response and their relationship at follow-up 
(supportive or very supportive; no change in relationship, other reactions, missing); and IV) 
HSV-2 symptoms (0,1); and sexual activity (0,1). Other measures included baseline audio 
computer-assisted survey items: age; gender; ever had sexual intercourse (0,1). At follow-
up, nurse researchers asked whether participants had tried to access HSV-2 treatment (most 
local clinics have acyclovir in stock, provided free of charge with a referral). From the 
laboratory analyses, we documented index values for Kalon and results of WB testing.
Data Analysis: We analyzed qualitative notes from nurse field researchers and coded 
responses for measures as described above. We compared the participants' interview 
response on sexual behavior to their baseline survey results and noted discordant results, and 
we compared self-reported sexual behavior and HSV-2 symptoms with WB results. PPV and 
negative predictive value (NPV) for the Kalon test were calculated from the estimated 
sensitivity (94%) and specificity (92%) of the test with the higher cut-off using standard 
formulas.
Human Subjects Protection
Institutional review boards at PIRE (USA) and the Moi University (Kenya) reviewed and 
approved study protocols, including consent procedures and disclosure procedures. Young 
adults aged 18 and older gave written consent, while guardians gave written permission and 
youth under 18 gave written assent for participation. To send samples out of the country for 
WB confirmatory testing, additional written consent was obtained.
RESULTS
From October 2011 to January 2012, 837 youth completed baseline survey and biomarker 
testing. The average age of participants was 14.9 years (SD 1.5; range 11–21 years). 
Twenty-eight adolescents (3.3%) were identified as HSV-2 positive by Kalon ELISA at 
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baseline, with an estimated prevalence of 4.4% for girls and 2.3% for boys. Another six 
were identified as indeterminate. Only participants with positive ELISA results were 
contacted for disclosure which was conducted from February 2012 through March 2013. 
Follow-up interviews were conducted within 3–9 months later.
At the observed HSV-2 seroprevalence the calculated NPV of the ELISA was 99.8%, 
providing high confidence in negative test results. However, the low calculated PPV of 
26.4% prompted investigator and IRB concerns that false positives could result in needless 
social and psychological distress. Thus, we modified our protocol and informed participants 
that serological results are not always accurate and could result in false positive values, and 
requested consent to send samples for WB confirmatory testing. All six of those with 
indeterminate results and 22 of those with positive results consented (five more were not 
found and one refused; Figure 1).
Despite the low calculated PPV of the Kalon test, > 90% of positive samples and > 80% of 
indeterminate samples were positive by WB (Table 1). Among the samples tested by WB, 
100% (9/9) with initial Kalon index values ≥ 2.5, 87.5% (14/16) with index values ≥ 1.5 and 
< 2.5, and 83% (5/6) with index values ≥ 0.9 and < 1.5 were confirmed positives. Using our 
study-specific algorithm, 2/22 positives (9%) were false positives. For samples with initial 
Kalon index values < 2.5, there was no association between the index value and WB result 
(data not shown).
Because we did not submit all samples for reference testing by WB, we cannot calculate 
valid sensitivity and specificity estimates for Kalon performance using the study-specific 
algorithm. However, the observed high rates of WB positives among samples submitted for 
confirmatory testing suggest that the sensitivity was lower than estimated (most 
indeterminants were true positives), and the specificity was higher than estimated (most 
positives were true positives). Among samples tested by WB, 26 had initial index values 
≥1.1 and would have been deemed positive according to the manufacturer's suggested cut-
off; three of these (11.5%) were negative by WB and would thus have been false positives.
Participant Reaction as Reported at Follow Up
About 28% of participants who received HSV-2 serologic test results (8/28) reported 
minimal stress and a positive attitude after disclosure. Another 50% said that they were 
worried or upset for a few days to a few weeks, but had eventually found ways to cope 
through support from their guardian, prayer, or hope that the result could be a false positive. 
Another 11% said they had been worried for a month or more, but eventually came to 
acceptance. The final group (11%) reported being very stressed for many months with 
adverse emotional, physical, social and/or academic effects. As an example, one participant 
was very distressed at follow up, as the family was convinced the youth was actually 
infected with HIV and not HSV-2, resulting in stigmatization and isolation. The nurse 
researcher assured the participant that this was not the case, and talked with family members 
to correct the misperception.
Males made up 36% of the sample, but were represented disproportionately among those 
with the most severe and lingering stress (66%). Females were most likely to be among 
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those with minimal stress (80%). Only two participants reported that they had sought 
treatment. In one case, the participant was told the clinic was out of the medication. The 
second went to a health center with the referral form and was given medicine. She reported, 
“the ulcers disappeared four days after taking the treatment.”
Guardian Reaction
Among the guardians present at initial disclosure, seven were mothers; four brother, sister, 
or sister-in-law; two stepmothers; seven grandparents; and eight aunts or uncles. Guardians 
of participants under 18 years of age were contacted for permission to speak with the child 
at follow-up, but in no case did the guardian choose to be present for the follow-up visit. 
Most guardians were perceived as being supportive or very supportive (61%) or showing no 
change in the way they related to the youth (17%). As an example of perceived support, one 
participant said of her Aunt, “were it not for her, I don't know how I would have made it.” 
Another boy said of his brother, “Nowadays he is more loving and concerned about my life. 
Before the disclosure we could not sit together to discuss anything but nowadays we discuss 
most things freely and kept on encouraging me to work hard in school.”
“Other reactions” included three guardians who were convinced that HSV-2 was actually a 
different disease (HIV or cancer). One guardian insisted the child take a medicine (likely a 
traditional medicine). Another mother told the researcher, “she likes men too much,” 
referring to the participant daughter. Among the three youth who reported the most severe 
and lingering stress, two reported negative attitudes from their guardian. No other pattern 
was found.
Sex, symptoms and WB
Of the 22 participants with positive samples and WB, only six (27%) reported ever having a 
sex partner (Table 2). Of these, three reported symptoms, and of these, one had reported 
virginity on the survey. Of the rest (16), 10 consistently reported no sexual contact (both 
interview and survey) and no symptoms; of these, two were WB negative (both males) while 
eight were positive. Of the final six, three reported sexual intercourse by survey but not 
interview, and three consistently denied sex but reported HSV-2 symptoms.
DISCUSSION
Using a higher than manufacturer cut-off (1.5 vs. 1.1), we found a relatively low prevalence 
of HSV-2 among orphaned 7th and 8th grade Kenya students, as compared to a 13–14 year 
old sample in the same region that was not limited to school-attending orphans.[9] We used 
a higher than manufacturer test cut-off, and with WB confirmatory testing, 91% of those 
who were positive by our algorithm and 83% of indeterminants were true positives. It is 
possible that estimates from studies using the manufacturer's cut-off may have had lower 
specificity, inflating prevalence. Our study, however, was not designed to formally evaluate 
the accuracy of the Kalon HSV-2 ELISA test; the goal was to optimize its performance for 
our specific study setting. Anticipating the potential trauma of informing adolescent subjects 
of a positive result, we opted to maximize specificity of the biomarker assay to minimize 
false-positives by increasing the cut-off to define a positive test. A priori, we accepted the 
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resulting decrease in sensitivity and any attendant false negative results, recognizing that 
negative predictive value would be minimally affected.
We found that youth were generally resilient in the disclosure of results. Most reported that 
they felt stressed and upset initially but, with support from their guardians, they soon 
accepted. Most orphaned participants described their guardians as supportive, even though 
few had a living parent to come with them for disclosure. In a few cases, however, 
participants reported feeling very stressed over prolonged periods of time.
We also found that the great majority of youth who were HSV-2 seropositive denied any 
sexual contact when interviewed. Since HSV-2 is almost always transmitted by direct sexual 
contact with an infected person [2, 31] this suggested that either the participant's self-report 
(corroborated or not by ACASI survey and symptoms) or the Kalon result was false. When 
examining WB results, we found that the two false positives samples corresponded to 
consistent verbal and survey reports denying sexual contact or symptoms. Eight others, 
however, likewise consistently denied sexual behavior or symptoms, suggesting inaccurate 
reporting.
A limitation of the present study is the small sample size of participants with both WB and 
qualitative (disclosure) data. Findings can only be generalized to adolescent orphans 
attending Grades 7 and 8 in western Kenya, almost all of whom were members of the Luo 
tribe. Since over 80% of indeterminants in our study were found to be WB positive, 
adjustments to our protocol may be needed in order to maximize both sensitivity and 
specificity of the ELISA test. A standardized measure for distress was not used. For future 
studies, we recommend using such a measure at follow-up.
In summary, the Kalon ELISA used with a higher than manufacturer recommended cut-off 
modestly reduced the rate of false positive test results but also increased false negatives. 
Investigators should carefully consider the relative benefits of increased confidence in 
positive test results versus the potential risk of missed positives in making such adjustments. 
They should also consider the risk-benefit ratio in deciding whether or not to disclose 
HSV-2 results to adolescent participants under specific field conditions. Including a parent/
guardian or trusted adult at disclosure, and following up with the youth a month later, may 
help to minimize psychosocial harm, especially for boys, who may be more vulnerable than 
girls.
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• The study is unique in examining the specificity of a common serological 
HSV-2 test along with adolescent outcomes of a culturally sensitive disclosure 
protocol.
• Using a modified algorithm for interpreting results, 91% of tested ELISA 
positive results were WB confirmed; 83% of ELISA indeterminants were WB 
positive.
• Boys in this study were more susceptible than girls to prolonged distress after 
HSV-2 disclosure.
• Self-reported virginity was highly inconsistent with WB-confirmed detection of 
HSV-2 antibodies.
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Table 1
HSV-2 Antibody Detection in Kenyan Adolescent Orphans.
Number of samples with result indicated / Total number tested (%) Kalon ELISA Testing
Index Value Range Initial Product Insert Final
a
Study Algorithm Final
b Positive by Western 
blot
≥ 2.5 12/837 (1.4) 12/12 (100) Positive 12/12 (100) Positive 9/9 (100)
≥ 1.5, < 2.5 16/837 (2.0) 16/16 (100) Positive 14/16 (87.5) Positive 2/16 (12.5) Indeterminate
13/14 (92.9) 1/2 
(50.0)
≥ 1.1, < 1.5 5/837 (0.6)
4/5 (80.0) Positive 2/5 (40.0) Positive 2/5 (40.0) Indeterminate 1/2 (50.0) 2/2 (100)
1/5 (20.0) Negative 1/5 (20.0) Negative ND
≥ 0.9, < 1.1 2/837 (0.2) 1/2 (50.0) Positive 1/2 (50.0) Indeterminate 2/2 (100) Indeterminate 2/2 (100)
< 0.9 802/837 (95.8) 802/802 (100) Negative 802/802 (100) Negative ND
ND, not done.
a
Final Kalon results determined according to the product insert, including repeat testing when applicable; no repeat ELISA testing was performed 
for initial index values ≥ 2.5 or < 0.9.
b
Final Kalon results determined according to the algorithm described in Methods.
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Table 2
Report of Sexual Behavior and Symptoms by gender and WB results among Kalon HSV-2 positive 
participants
Gender Age at Baseline (Oct. 2011)
Reported sexual 
contact in interview
Reported Sex on 
Survey Reported HSV2 Symptoms
HSV2 Western blot 
result
F 13 0 1 0 positive
F 13 0 0 1 positive
F 14 0 0 0 positive
F 14 0 0 0 positive
F 14 1 1 1 positive
F 15 0 0 0 positive
F 15 0 1 0 positive
F 15 0 0 1 positive
F 15 1 1 1 positive
F 16 0 0 0 positive
F 17 0 0 0 positive
F 17 1 1 0 positive
F 20 0 0 0 positive
M 12 0 0 1 positive
M 13 0 0 0 negative
M 14 1 1 0 positive
M 14 0 1 0 positive
M 15 0 0 0 negative
M 15 1 0 1 positive
M 15 0 0 0 positive
M 15 0 0 0 positive
M 17 1 1 0 positive
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